




**CERTIFICATE OF MAILING**

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail under 37 C.F.R. 1.8 on the date indicated below and is addressed to: MAIL STOP: AMENDMENT; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: December 7, 2004

  
Selena Whitaker-Paquet

JFW

Attorney Docket No.: 11311.1002U

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: **Reiner LAUS, Mitchell GOLD, Madhusudan PESHWA, Grant PICKERING,  
Jelle KYLSTRA (as amended)**

Group Art Unit: 1646

Application No. : 10/666,122

Filing Date : September 19, 2003

For : **IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS FOR THE  
TREATMENT OF MODERATELY TO WELL-DIFFERENTIATED CANCERS**

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

**MAIL STOP: AMENDMENT**  
COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir or Madam:


Enclosed for filing in the above-referenced patent application are the following:

Transmitted herewith for filing is the following:

1. Information Disclosure Statement;
2. PTO Form /SB/08 (Substitute for form 1449A/PTO) w/attached 13 references; and
3. Return-receipt postcard.

The Commissioner is hereby authorized to charge any additional fees, which may be required in connection with the filing of these documents, or credit any overpayment to Deposit Account No. 19-3555. This document is filed in duplicate.

Respectfully submitted,

  
Gary M. Myles  
Registration No. 46,209

Date: December 7, 2004

SPECKMAN LAW GROUP PLLC  
**20601**



**CERTIFICATE OF MAILING**

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail under 37 C.F.R. 1.8 on the date indicated below and is addressed to: **MAIL STOP: A MENDMENT**; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: December 7, 2004

Selena Whitaker-Paquiet

Attorney Docket No.: 11311.1002U  
**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: **Reiner LAUS, Mitchell GOLD, Madhusudan PESHWA, Grant PICKERING,  
Jelle KYLSTRA (as amended)**

Group Art Unit: 1646

Application No. : 10/666,122

Filing Date : September 19, 2003

For : **IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS FOR THE  
TREATMENT OF MODERATELY TO WELL-DIFFERENTIATED CANCERS**

**INFORMATION DISCLOSURE STATEMENT**

**MAIL STOP: AMENDMENT**  
COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir or Madam:

The attached form PTO/SB/08 (substitute for form 1449A/PTO) identifies five (5) U.S. patent references; one (1) U.S. patent application reference; five (5) published international application references; and eight (8) literature references. Pursuant to 35 CFR 1.98 (2)(ii), copies of the international published applications and literature references are enclosed herewith for the Examiner's convenience. Copies of cited U.S. patents and patent applications are not submitted with this Information Disclosure Statement.

The documents listed on the accompanying form PTO/SB/08 are cited in compliance with the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, as amended. Applicant does not concede that the references are "prior art" under 35 U.S.C. §102 or §103, and specifically reserves the right toantedate such materials, as by a showing under 37 C.F.R. § 1.131 or otherwise.

Some of these references were cited in an International Search Report for a corresponding PCT application. This Information Disclosure Statement is being filed within three (3) months of receipt of the International Search Report and prior to receipt of any substantive Office Action; therefore, no fee or certification is required.

Respectfully submitted,



Gary M. Myles  
Registration No. 46,209


Date: December 7, 2004

SPECKMAN LAW GROUP PLLC

**20601**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
			Application Number	10/666,122	
			Filing Date	September 19, 2003	
			First Named Inventor	Reiner Laus, et al.	
			Art Unit	1646	
			Examiner Name		
Sheet	1	of	Attorney Docket Number	11311.1002U	



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-2004/0161413 A1	Aug. 19, 2004	Laus, et al.	
	2	US-6,210,662 B1	Apr. 3, 2001	Laus, et al.	
	3	US-6,080,409	Jun. 27, 2000	Laus, et al.	
	4	US-5,976,546	Nov. 2, 1999	Laus, et al.	
	5	US-5,215,926	Jun. 1, 1993	Etchells, III, et al.	
	6	US-4,927,746	May 22, 1990	Dorn	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Country code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	1	WO 01/25273 A2	Apr. 12, 2001	Corixa Corporation	
	2	WO 92/07243 A1	Apr. 30, 1992	Cellpro Incorporated	
	3	WO 91/16116	Oct. 31, 1991	Cellpro Incorporated	
	4	WO 89/06280	Jul. 13, 1989	Du Pont De Nemours and Company	
	5	WO 86/03225	Jun. 5, 1986	Schering Biotech Corporation	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	1	CAMPTON, Kristina, et al.; "Tumor Antigen Presentation by Dermal Antigen-Presenting Cells," <i>The Journal of Investigative Dermatology</i> , Vol. 115, No. 1, pp. 57-61 (July 2000)			
	2	CRAWFORD, E. David, et al.; "Proposed Substages for Metastatic Prostate Cancer," <i>Urology</i> , Vol. 50, No. 6, pp. 1027-1028 (1997)			
	3	HSU, Frank J., et al.; "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," <i>Nature Medicine</i> , Vol. 2, No. 1, pp. 52-58 (1996)			
	4	KUNDU, Smriti K., et al.; "A Pilot Clinical Trial of HIV Antigen-Pulsed Allogeneic and Autologous Dendritic Cell Therapy in HIV-Infected Patients," <i>AIDS Research and Human Retroviruses</i> , Vol. 14, No. 7, pp. 551-560 (1998)			
	5	PESHWA, Madhusudan V., et al.; "Induction of Prostate Tumor-Specific CD <sup>8+</sup> Cytotoxic T-Lymphocytes In Vitro Using Antigen-Presenting Cells Pulsed With Prostatic Acid Phosphatase Peptide," <i>The Prostate</i> , Vol. 36, No. 1, pp. 129-138 (1998)			
	6	GLEASON, Donald F., et al.; "Histologic Grading and Clinical Staging of Prostatic Carcinoma," <i>Urologic Pathology: The Prostate</i> , pp. 171-197 (1977)			
	7	FLAMAND, V., et al.; "Murine Dendritic Cells Pulsed In Vitro With Tumor Antigen Induce Tumor Resistance In Vivo," <i>Eur. J. Immunol.</i> , Vol. 24, No. 3, pp. 605-610 (March 1994)			
	8	HAMAOKA, T., et al.; "Induction of Tumor-Specific In Vivo Protective Immunity by Immunization with Tumor Antigen-Pulsed Antigen-Presenting Cell," <i>ABSTRACT, Princess Takamatsu Symp.</i> , Vol. 19, pp. 265-275 (1988)			

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.